🔎 Trials Near Me

Utama › Melanoma › Pennsylvania › Pittsburgh

Kajian klinikal Melanoma di Pittsburgh, PA

31 kajian untuk Melanoma sedang mencari peserta di lokasi dalam dan sekitar Pittsburgh (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

Mengambil pesertaFasa 3
  • University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06246916

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Mengambil pesertaFasa 3
  • Allegheny Health Network, Pittsburgh
Umur 18 hingga 70 · Semua jantina · Dikemas kini 24 Sep 2026 · NCT05727904

A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information

Mengambil pesertaFasa 2
  • Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Sehingga umur 25 · Semua jantina · Dikemas kini 24 Sep 2026 · NCT07621614

Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

Mengambil pesertaFasa 3
  • UPMC Hillman Cancer Center, Pittsburgh
Umur 75 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT07068074

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

Mengambil pesertaFasa 2
  • University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Sep 2026 · NCT04511013

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

Mengambil pesertaFasa 1/2
  • UPMC Hillman Cancer Center, Pittsburgh
Umur 18 ke atas · Semua jantina · Dikemas kini 31 Ogo 2026 · NCT05896839

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Mengambil pesertaFasa 1/2
  • Children's Hospital of Pittsburgh of UPMC, Pittsburgh
12 Months – 30 Years · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT04851119

Project: Every Child for Younger Patients With Cancer

Mengambil pesertaKajian pemerhatian
  • Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Sehingga umur 25 · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT02402244

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Mengambil pesertaFasa 1/2
  • Research Site, Pittsburgh
Umur 18 ke atas · Semua jantina · Dikemas kini 19 Ogo 2026 · NCT07115043

Investigating Real-Time Immunotherapy Symptoms Study

Mengambil peserta
  • UPMC Hillman Cancer Center, Pittsburgh
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Ogo 2026 · NCT07280715

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

Mengambil pesertaFasa 1/2
  • Allegheny Research Institute (Melanoma/NSCLC), Pittsburgh
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Jul 2026 · NCT06060613

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Mengambil pesertaFasa 2
  • UPMC Hillman Cancer Center, Pittsburgh
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Jun 2026 · NCT04114136

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

Mengambil pesertaFasa 1/2
  • UPMC Hillman Cancer Center, Pittsburgh
Umur 18 hingga 70 · Semua jantina · Dikemas kini 11 Jun 2026 · NCT05361174

Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma

Mengambil pesertaKajian pemerhatian
  • UPMC Hillman Cancer Center, Pittsburgh
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Jun 2026 · NCT04658303

Evaluation of Hypoxia in Primary Melanoma

Mengambil pesertaKajian pemerhatian
  • UPMC Hillman Cancer Center, Pittsburgh
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Jun 2026 · NCT06831071

MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

Mengambil pesertaFasa 1/2
  • UPMC Hillman Cancer Center, Pittsburgh
Umur 18 hingga 90 · Semua jantina · Dikemas kini 10 Jun 2026 · NCT05655312

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

Mengambil pesertaFasa 1/2
  • University of Pittsburgh Medical Center, Pittsburgh
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Mei 2026 · NCT03686124

Neoadjuvant Darovasertib in Primary Uveal Melanoma

Mengambil pesertaFasa 3
  • UPMC Hillman Cancer Center, Pittsburgh
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Mei 2026 · NCT07015190

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

Mengambil pesertaFasa 1/2
  • University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Apr 2026 · NCT06413680

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

Mengambil pesertaFasa 1
  • UPMC Hillman Cancer Center, Pittsburgh
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Apr 2026 · NCT06326411

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

Mengambil pesertaFasa 2
  • UPMC Hillman Cancer Center, Pittsburgh
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Apr 2026 · NCT07223424

RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis

Mengambil pesertaFasa awal 1
  • UPMC Hillman Cancer Center, Pittsburgh
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Apr 2026 · NCT06216938

A Study of VET3-TGI in Patients With Solid Tumors

Mengambil pesertaFasa 1
  • UPMC- Hillman Cancer Center, Pittsburgh
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Apr 2026 · NCT06444815

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Mengambil pesertaFasa 2/3
  • UPMC Hillman Cancer Center, Pittsburgh
Semua umur · Semua jantina · Dikemas kini 2 Apr 2026 · NCT06581406

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Mengambil pesertaFasa 3
  • UPMC Hillman Cancer Center, Pittsburgh
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Feb 2026 · NCT05549297

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

Mengambil pesertaKajian pemerhatian
  • UPMC Hillman Cancer Center, Pittsburgh
Umur 18 ke atas · Semua jantina · Dikemas kini 26 Jan 2026 · NCT06599619

Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

Mengambil pesertaFasa 1/2
  • University of Pittsburgh Medical Center, Pittsburgh
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Okt 2025 · NCT06249048

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

Mengambil pesertaFasa 1/2
  • University of Pittsburgh Medical Center, Pittsburgh
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Okt 2025 · NCT04370587

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

Mengambil pesertaFasa 1/2
  • UPMC Hillman Cancer Center, Pittsburgh
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Mei 2025 · NCT05970497

Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

Mengambil pesertaFasa 1/2
  • University of Pittsburgh, Pittsburgh
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Dis 2024 · NCT05877430

Kajian Melanoma di bandar lain

Kajian lain di Pittsburgh

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.